Objective: In patients with cardiovascular disease or organ failure, elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) are associated with an increased risk of future cardiovascular events. We aimed to investigate elevated plasma ADMA concentrations as a prospective risk marker for adverse events in patients undergoing noncardiac surgery.

Design: Prospective observational study.

Setting: Two tertiary care centers.

Patients: Four hundred and two patients scheduled for elective noncardiac surgery.

Interventions: None.

Measurements And Main Results: Patients were followed for 30 days after surgery for a predefined composite end point (death, myocardial infarction/acute coronary syndrome, acute heart failure, severe arrhythmia, embolism, or thrombosis). Plasma ADMA concentrations at baseline were determined by high-performance liquid chromatography. ADMA was only weakly (-0.2 < tau < 0.2) correlated with other risk markers and risk scores. In univariate logistic regression, per 0.1-micromol/L increment in plasma ADMA concentration, the odds ratio to experience the primary end point increased by 1.26 (95% confidence interval 1.10-1.45, p = .001). In a multivariate logistic regression model adjusting for age, gender, current smoking, plasma creatinine, hypertension, diabetes, ischemic heart disease, highly sensitive C-reactive protein, revised cardiac risk index, type of surgery, high-risk surgery, ASA class, and study center, ADMA was found to be an independent risk marker. The odds ratio to experience the primary end point was 1.33 (95% confidence interval 1.12-1.59, p = .001) per 0.1-micromol/L increase in the plasma ADMA concentration.

Conclusions: Elevated plasma ADMA concentrations are independently associated with a higher risk for adverse events in the peri- and postoperative periods.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.CCM.0000277038.11630.71DOI Listing

Publication Analysis

Top Keywords

plasma adma
20
elevated plasma
16
adverse events
12
adma concentrations
12
plasma concentrations
8
concentrations endogenous
8
endogenous nitric
8
nitric oxide
8
oxide synthase
8
synthase inhibitor
8

Similar Publications

Clinical and biochemical factors associated with amygdalar metabolic activity.

NPJ Aging

January 2025

Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Japan.

We investigated clinical factors and biochemical markers associated with amygdalar metabolic activity evaluated by [F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) in 346 subjects without a history of malignant neoplasms. Univariate regression analysis revealed significant relationships between amygdalar metabolic activity and fasting plasma glucose (FPG), glycated hemoglobin, coronary artery disease (CAD) history, aspirin use, oral hypoglycemic agents (OHAs) use, and asymmetric dimethylarginine (ADMA). In multiple stepwise regression analysis, FPG and CAD history were independently associated with amygdalar metabolic activity.

View Article and Find Full Text PDF

Objectives: Nonsmall cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Asymmetric dimethylarginine (ADMA) is an emerging molecule that is highlighted in carcinogenesis and tumor progression in lung cancer. Since elevated concentrations of ADMA are observed in lung cancer patients, we aimed to explore its associations with inflammation markers and established prognostic indices.

View Article and Find Full Text PDF

l-arginine derivatives (ADMA, SDMA, NMMA) are endogenous inhibitors of nitric oxide (NO֗) production, which is essential in critical brain processes including blood-brain barrier (BBB) integrity and long-term potentiation (LTP). ADMA and NMMA are degraded by dimethylarginine dimethylaminohydrolase 1 (DDAH1) and protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues. There is no data concerning the impact of metabotropic glutamate receptors (mGlu) ligands on this aspect of brain physiology.

View Article and Find Full Text PDF

The l-Arginine pathway may act as a mediator in the association between impaired one-carbon metabolism and hypertension.

Biochimie

November 2024

Unitat de Medicina Preventiva, ANUT-DSM, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, (FMCS URV), Spain; IISPV, Areas of Family and Community Medicine, Spain; CIBERobn ISCIII, Spain. Electronic address:

Article Synopsis
  • Elevated levels of fasting plasma total homocysteine (tHcy) and a specific genetic variant (methylenetetrahydrofolate reductase C677T polymorphism) are linked to hypertension, but the role of the l-Arginine pathway was previously unclear.
  • A study involving 788 adults found that higher tHcy levels were positively related to two metabolites (ADMA and SDMA) and negatively associated with the l-Arginine/ADMA ratio, indicating a potential protective effect against hypertension.
  • The analysis suggested that both tHcy and ADMA play intermediary roles in how the genetic variant affects hypertension risk, highlighting the importance of the l-Arginine pathway in this relationship.
View Article and Find Full Text PDF

L-Arginine is the physiological substrate for the nitric oxide synthase (NOS) family, which synthesises nitric oxide (NO) in endothelial and neuronal cells. NO synthesis can be inhibited by endogenous asymmetric dimethylarginine (ADMA). NO has explicit roles in cellular signalling and vasodilation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!